Prevnar 13 2.2 mcg

PREVNAR 13 2.2 MCG is a pneumococcal vaccine designed to protect against pneumococcal disease. This suspension is administered intramuscularly and is manufactured by Pfizer Canada ULC.

PREVNAR 13 2.2 MCG is used to help prevent pneumococcal disease caused by the pneumococcal polysaccharide serotype 14. This vaccine is typically recommended for individuals who are at increased risk of pneumococcal infection, such as young children and adults with certain medical conditions. It works by stimulating the body's immune system to produce antibodies against the pneumococcus bacteria, which can help prevent infection.

Common effects of PREVNAR 13 2.2 MCG may include redness, swelling, or pain at the injection site. Some individuals may also experience mild fever, fatigue, or headache after receiving the vaccine. These effects are usually temporary and resolve on their own within a few days.

Before receiving PREVNAR 13 2.2 MCG, inform your healthcare provider about any allergies, especially to any components of the vaccine. It is important to discuss your medical history, including any recent illnesses or immunizations. The vaccine should be stored and handled according to the manufacturer's guidelines to ensure its effectiveness.

PREVNAR 13 2.2 MCG may interact with other medications or vaccines. It is important to inform your healthcare provider about all the medications you are taking, including over-the-counter drugs, supplements, and other vaccines. Alcohol and certain medications may affect the immune response to the vaccine, so it is advisable to discuss any potential interactions with a healthcare professional.